Glucocorticoid

Initial biologic therapy is now the most common treatment for children with systemic juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry, according to data presented at ACR Convergence 2021.

Patients with chronic inflammatory disease on immunosuppressants, especially B-cell depleting agents, mycophenolate and glucocorticoids, exhibited poor antibody responses to the mRNA vaccine for COVID-19, according to a presenter here.

Tocilizumab plus glucocorticoids is beneficial for patients with COVID-19 who require oxygen therapy, according to updated EULAR “points to consider” on the use of immunomodulatory therapies in SARS-CoV-2.

Healthy adults with the highest sensitivity to glucocorticoids have a proteomic profile suggesting a greater capability for responding to stressful stimuli compared with those with lowest sensitivity, according to study data.

In patients with acute exacerbation of idiopathic pulmonary fibrosis, adding IV cyclophosphamide to high-dose glucocorticoids increased mortality at 3 months, researchers reported at the European Respiratory Society International Congress.

Adding mycophenolate mofetil to a glucocorticoid in first-line treatment for immune thrombocytopenia improves response and decreases the risk for refractory or relapsed disease, according to data.

Nearly 90% of adults with chronic inflammatory disease who were taking immunosuppressive medication had an antibody response after receiving an mRNA vaccine for SARS-CoV-2, according to findings in Annals of Internal Medicine.

Patients with rheumatoid arthritis who receive even low daily doses of glucocorticoids are at a 59% increased risk for clinical vertebral fracture, according to data published in Rheumatology.

Daily glucocorticoid doses of 5 mg or more during the preceding 6 or 12 months is associated with an increased risk for cardiovascular events in steroid-naïve patients with rheumatoid arthritis, according to data.

Biologic initiation in children hospitalized with new-onset systemic juvenile idiopathic arthritis increased significantly from 2008 to 2019, reaching 40% between 2017 and 2019, and may be linked with reduced glucocorticoid use, according to data.